Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers C > Headlines for Cypress Bioscience Inc. > News item |
Jefferies rates Cypress at buy
Jefferies & Co., Inc. analyst Adam Walsh rated Cypress Bioscience, Inc. at buy. The analyst believes shares will continue to trend higher in relation to the phase 3 milnacipran data, which is on-track for mid-2007. Shares of the San Diego-based pharmaceutical company were up 14 cents, or 1.78%, at $8.02. (Nasdaq: CYPB)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.